Two Conferences, One Location, One Week

JUNE 7-9, 2015
eagleson.org/IBC

Beyond the ABCs of IBCs
Institutional Biosafety Committee Conference

JUNE 9-11, 2015
eagleson.org/OCC

&

Preventing and Treating Biological Exposures
Occupational Health Colloquium

More Information Online
eagleson.org/211

Preventing and Treating Biological Exposures is Presented in partnership with the Eagleson Institute and the Elizabeth R. Griffin Research Foundation
A block of rooms has been reserved at the The Lafayette Park Hotel and Spa at the special rate of $174/Night. To make reservations at that rate, call (925) 283-3700 and mention the “Occupational Health Colloquium” or “IBC Conference.” Close to Oakland and San Francisco Airports.
Robert Kosnik, MD, Medical Director, University of California San Francisco Occupational Health Services

Dr. Robert Kosnik is a certified occupational medicine specialist in both the U.S. and Canada. In Canada, his practice provided professional services for more than 20 years to a variety of industry sectors, including health care. At UCSF, Dr. Kosnik provides leadership to Occupational Health Services with a focus on maintaining the health of the staff and preventing the transmission of communicable diseases in the UCSF Medical Center and the research laboratories.

Dr. Kosnik has contributed to professional associations as a past president of the Occupational and Environmental Association of Canada, a past chair of the examination committee for the Royal College of Physicians and Surgeons of Canada in the specialty of occupational medicine, and president of the Association of Occupational and Environmental Clinics in the United States. He is a clinical professor of medicine in the Division of Occupational and Environmental Medicine at UCSF.

Wednesday, June 10, 2015, 8:45 AM

RESEARCH ON HIGHLY INFECTIOUS DISEASES: IMPLICATIONS FOR OCCUPATIONAL HEALTH

Stanley B. Prusiner, MD, Director, Institute for Neurodegenerative Diseases and Professor of Neurology and Biochemistry, University of California San Francisco

Nobel Laureate Stanley B. Prusiner, MD, is Director of the Institute for Neurodegenerative Diseases and Professor of Neurology and Biochemistry at the University of California San Francisco (UCSF). Dr. Prusiner’s groundbreaking discovery of prions – once considered heretical – has won him not only the 1997 Nobel Prize in Physiology or Medicine, but also numerous awards and recognition across the globe.

Dr. Prusiner’s research with prions has taken him from examining the cause of scrapie and mad cow disease in animals, to studying their role in Creutzfeldt-Jakob disease (CJD) in humans, and more recently to investigating the part prions may play in Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), the frontotemporal dementias (FTDs), chronic traumatic encephalopathy (CTE) and multiple system atrophy (MSA). Much of Dr. Prusiner’s current research focuses on developing therapeutics that reduce the levels of the specific prions responsible for each of these diseases.

The IBC Conference is indeed fortunate to have such a distinguished keynote speaker, one who has a fascinating story!

Monday, June 8, 2015, 1:00 PM

PRIONS AND NEURODEGENERATION: PROBLEMS WITH BIOCONTAINMENT, EFFECTIVE THERAPEUTICS, AND REVOLUTIONARY THOUGHTS

Stanley B. Prusiner, MD, Director, Institute for Neurodegenerative Diseases and Professor of Neurology and Biochemistry, University of California San Francisco

Nobel Laureate Stanley B. Prusiner, MD, is Director of the Institute for Neurodegenerative Diseases and Professor of Neurology and Biochemistry at the University of California San Francisco (UCSF). Dr. Prusiner’s groundbreaking discovery of prions – once considered heretical – has won him not only the 1997 Nobel Prize in Physiology or Medicine, but also numerous awards and recognition across the globe.

Dr. Prusiner’s research with prions has taken him from examining the cause of scrapie and mad cow disease in animals, to studying their role in Creutzfeldt-Jakob disease (CJD) in humans, and more recently to investigating the part prions may play in Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), the frontotemporal dementias (FTDs), chronic traumatic encephalopathy (CTE) and multiple system atrophy (MSA). Much of Dr. Prusiner’s current research focuses on developing therapeutics that reduce the levels of the specific prions responsible for each of these diseases.

The IBC Conference is indeed fortunate to have such a distinguished keynote speaker, one who has a fascinating story!
Beyond the ABCs of IBCs
Institutional Biosafety Committee Conference

Presented By: The Eagleson Institute Cosponsored By: The American Association for Laboratory Animal Science (AALAS), The American Biological Safety Association (ABSA), and American College of Laboratory Animal Medicine (ACLAM)

MONDAY, JUNE 8, 2015

8:30 WELCOME AND INTRODUCTIONS
Mary Ann Sondrini, EdM, Eagleson Institute

8:45 DUAL USE RESEARCH OF CONCERN (DURC)
Kathryn Harris, PhD, RBP, Senior Outreach & Education Specialist, NIH OBA; Robert Ellis, PhD, CBSP, DACVM (Hon), Director of Biosafety, Colorado State University; Ellyn Segal, PhD, Biosafety Manager, Stanford University

By September 25, 2015, all institutions subject to the U.S. Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern must be in compliance with its provisions. This session will review policy details, offer information about where to find implementation guidance, and provide details about relevant tools and educational materials. Two biosafety professionals, one from an institution conducting work with select agents and one without, will discuss the administrative aspects of establishing an Institutional Oversight Program for DURC.

10:15 BREAK

10:45 PROTOCOL REVIEW ACTIVITY
Elizabeth Gilman Duane, MS, RBP, CBSP, Associate Director, Environmental Health & Engineering

In this session, participants will examine two sample protocols, answering questions such as:
- Do your organization have a process in place for protocol review?
- Does the protocol provide enough information for a review to be conducted?
- What are the review steps?
- Does the protocol have factors that would raise containment level?
- What are the issues that need extra consideration?
- Is it a Major Action?
- Does the protocol fit the DURC criteria?

12:00 LUNCH

KEYNOTE

1:00 PRIONS AND NEURODEGENERATION:
PROBLEMS WITH BIOCONTAINMENT,
effective therapeutics, and revolutionary thoughts
Stanley B. Prusiner, MD, Director, Institute for Neurodegenerative Diseases and Professor of Neurology and Biochemistry, University of California San Francisco

2:00 INCIDENT REPORTING
Kathryn Harris, PhD, RBP, Senior Outreach & Educational Specialist, NIH OBA

An overview of the incident reporting requirements under the NIH Guidelines, including what issues are reportable and the timeframes for reporting. Elements of the NIH OBA incident reporting template will be discussed along with what OBA is looking for regarding an institution’s response to an incident.

2:30 BREAK

3:00 HUMAN GENE TRANSFER STUDIES
Tony Reid, MD, PhD, Professor of Medicine, University of California San Diego; Karen Byers, MS, RBP, CBSP, Biosafety Officer, Dana Farber Cancer Institute; Chris Jenkins, PhD, MPH, RBP, CHMM, Senior Vice President of Biosafety and Gene Therapy, WCG Biosafety

Dr. Tony Reid, a world renowned oncology physician who is recognized for his outstanding clinical research in colon
and pancreatic cancers, will begin this session with an overview of the progress made in cancer human gene transfer trials. He will share the challenges of being a trial PI, as well as his experiences serving as the human gene transfer expert on an IBC. Karen Byers will follow with a presentation on the “Procedures for Screening, Review, and Implementation of 80+ Human Gene Transfer Trials”, based on her experience as a biosafety officer at Dana Farber. Dr. Chris Jenkins, a biosafety specialist who consults with multiple organizations, will discuss the “Challenges for Local Sites in Multi-Center Trials Involving Human Gene Transfer.” Time will be left at the end for audience discussion.

5:00 CONCLUSION

TUESDAY, JUNE 9, 2015

8:30 INACTIVATION OF PATHOGENS AND TOXINS
Elizabeth Gilman Duane, MS, RBP, CBSP, Associate Director, Environmental Health & Engineering; Richie Fink, CBSP, Biosafety Consultant
In this session, participants will review considerations for designing and validating inactivation protocols to ensure effectiveness and allow for safe removal of materials (both pathogens and biological toxins) from higher containment. Relevant information that an IBC should request and review will also be discussed.

10:00 BREAK

10:30 VIVARIUM ISSUES
Carolyn Keierleber, PhD, Director, Scripps Research Institute; Timothy Mandrel, DVM, DACLAM, Professor and Chair, University of Tennessee
This session will examine how teamwork between the IBC, IACUC and vivarium staff can greatly enhance best safety practices. Discussion will include issues such as:

- How do we house animals treated with recombinant DNA?
- Can animals treated with viral vectors be removed from containment after a certain length of time?
- What if the vector is replication-defective?
- How does one show that a vector is defective?
- How do we know if the vector is no longer being shed?
- What is contaminated bedding and when does bedding require special treatment?
- Is it proper to label an animal cage with hazardous chemical signage if the chemical has been diluted to below hazardous levels?
- How does one know if a dilution is below hazardous levels, is an LD50 enough?
- Can a carcinogen or teratogen be diluted to a “safe” level? If so, is labeling for carcinogens required?
- How do we best communicate risks associated with animal research to animal workers?
- One size training does not fit all, there are various demographics in vivaria.
- Does everyone who works with animals need an allergy risk assessment or medical prophylaxis, both animal husbandry personnel as well as researchers?
- What role does the IBC play?

12:00 LUNCH

1:00 OCCUPATIONAL HEALTH: INTEGRATION OF IBCs AND OCCUPATIONAL HEALTH
Carolyn Keierleber, PhD, Director, Scripps Research Institute; Richard Whittman, MD, Occupational Medicine, Stanford University; Steve Munday, MD, MPh, Occupational Medicine, Sharp Rees-Stealy Medical Group
This session will include a discussion of ways that the IBC and Occupational Health personnel can optimize communication. In today’s research, IBCs are playing ever important roles in determining the occupational health issues associated with the use of microorganisms in research whether they are recombinant, attenuated, lab-adapted, or wild type. We require a strong communication process between the physician or health care provider and the scientists who are knowledgeable about the agents in use. IBCs and biosafety officers in particular must be the bridge between the two groups. Especially important is the fact that in some research projects, the IBC have information that an occupational medicine physician may have never previously encountered. Two renowned “Occ Docs” will speak about their personal experiences in this critical area.

2:30 REFLECTION ACTIVITY
Attendees are encouraged to share suggestions and ideas for shaping future policy.

3:00 CONCLUSION

eagleson.org/IBC
Presented By: The Eagleson Institute in partnership with the Elizabeth R. Griffin Research Foundation. Cosponsored By: The American Association for Laboratory Animal Science (AALAS), American Association of Occupational Health Nurses (AAOHN), American Biological Safety Association (ABSA), American College of Laboratory Animal Medicine (ACLM), and American College of Occupational and Environmental Medicine (ACOEM)

WEDNESDAY, JUNE 10, 2015

8:30 WELCOME AND INTRODUCTIONS
Mary Ann Sondrini, EdM, Eagleson Institute
James M. Welch, Elizabeth R. Griffin Research Foundation

8:45 KEYNOTE: RESEARCH ON HIGHLY INFECTIOUS DISEASES: IMPLICATIONS FOR OCCUPATIONAL HEALTH
Robert Kosnik, MD, Medical Director, UCSF Occupational Health Services
Dr. Robert Kosnik, a certified occupational medicine specialist in the U.S. and Canada, is director of Occupational Health Services at University of California San Francisco Medical Center. Prior to joining UCSF, Dr. Kosnik was Medical Director, Employees’ Health Services, St. Michael’s Hospital, Toronto, where he was on the front lines of Canada’s SARS outbreak. His background gives him a unique perspective on the occupational health issues surrounding emerging diseases.

“PREVENTING AND TREATING BIOLOGICAL EXPOSURES” IS A UNIQUE EVENT THAT PROVIDES AN OPPORTUNITY TO EXAMINE THE LATEST ISSUES FACING THOSE WHO PROVIDE OCCUPATIONAL MEDICAL SERVICES TO LABORATORY PERSONNEL AS WELL AS NETWORK AND DEVELOP LONG-LASTING RELATIONSHIPS WITH COLLEAGUES FROM AROUND THE COUNTRY.

9:45 PANEL: BREAKING NEW GROUND, BUILDING NEW CONNECTIONS
Paula DesRoches, ANP-BC, COHN-S, Emory Healthcare and Emory University; Maureen Thompson, BSN, RN, Emory University; Participated by: James M. Welch
For the panelists, the past year required their institutions’ lab/clinical staff, research/healthcare, infection control doctors and nurses/biosafety officers to work together—often for the first time. Together, the panel will describe lessons learned and explain how they are strengthening, and maintaining the new connections that developed during the Ebola crisis.

10:45 BREAK

11:05 PPE: SUITED TO THE TASK
Natasha Griffith, MS, University of California-Los Angeles; Maureen Thompson, BSN, RN, Emory University
This presentation will focus on what occupational medicine can learn from biosafety about Personal Protective Equipment (PPE). It will include an explanation of PPE used for infection control and biosafety; an in-depth description of types and materials, and how they should be worn; some of the science behind the standards; and a discussion of the risks of donning and doffing.

12:15 LUNCH

1:15 OCCUPATIONAL HEALTH IMPLICATIONS OF NEWER RESEARCH TOOLS
Gary Fujimoto, MD, Occupational Medical Consultant; T. Warner Hudson, MD, FACOEM, FAAFP, UCLA Health System and Campus
This session will focus on risk assessment, surveillance and post-exposure assessment and prophylaxis of immortalized human cells and primary human cells, human cells in permissive animal hosts, and lentiviral and retroviral vectors.

3:15 BREAK

3:35 EXPLORATION OF DRAFT GUIDELINES FOR BEST PRACTICES FOR MANAGEMENT OF A RESEARCH WORKER EXPOSED TO VIRAL VECTOR SYSTEMS
Moderator: Mary Ann Sondrini, EdM, Eagleson Institute
This session will allow participants to study and comment on draft practices being developed by Jatin M. Vyas, MD, PhD; T. Warner Hudson, MD, FACOEM, FAAFP; and Gary R. Fujimoto, MD. The moderated discussion will allow...
attendees to share best practices as well as provide invaluable information to the authors as they work toward publishing the guidelines.

5:00 CONCLUSION

THURSDAY, JUNE 11, 2015

8:30 BREATHE EASY
Speaker Now Being Confirmed
This panel presentation will describe the risks, common potential exposures, mitigation, and surveillance of chemicals commonly used in animal research, such as anesthetic gases, OSHA-regulated chemicals such as formaldehyde, and other hazardous chemicals such as MPTP. Administration and use of chemicals, industrial hygiene programs, and disposal of waste chemicals and contaminated bedding will be addressed. Interfacing and collaborating with occupational medicine professionals will be highlighted. Practical information will be shared that can be used to augment an existing vivarium safety program or to facilitate the establishment of a program.

9:30 PREVENTION OF LAB ANIMAL ALLERGY
Gregg M. Stave, MD, JD, MPH, Duke University Medical Center
Allergic reactions are among the most common conditions affecting the health of workers involved in the care and use of research animals. This presentation will address approaches to dealing with the issue.

10:30 BREAK

10:50 OLDIES BUT BADDIES
T. Warner Hudson, MD, FACOEM, FAAFP, UCLA Health System and Campus; Natasha Griffith, MS, University of California-Los Angeles; Timothy D. Mandrell, DVM, DACLAM, University of Tennessee Health Science Center
This session will provide new information about diseases that have been around for years—but still present problems for laboratory workers and the occupational health professionals safeguarding them, such as TB, Burkholderia, Brucellosis, Aquatic Mycobacteria, and LCMV.

11:50 LUNCH

12:50 ENGAGE THE SPEAKERS
Colloquium Speakers
This session provides participants an opportunity to engage with the colloquium speakers of their choice in two 30-minute small group discussions.

1:50 WRITING PROTOCOLS IN AN EMERGENCY: LESSONS LEARNED AT EMORY
Paula DesRoches, ANP-BC, COHN-S, Emory Healthcare and Emory University; Maureen Thompson, BSN, RN, Emory University
Occupational health professionals involved with the Ebola incidents at Emory will share the policies and protocols that were developed during that emergency and provide pointers for those who may have to quickly develop protocols in the future.

2:50 BREAK

3:05 “HOT ZONES” AND HOT TOPICS
T. Warner Hudson, MD, FACOEM, FAAFP, UCLA Health System and Campus
This presentation will include emerging threats and the latest developments in surveilling and treating biological exposures. Possible topics include measles and mosquito-borne viruses such as West Nile, chikungunya, dengue, and yellow fever.

4:05 WRAP-UP AND IDEAS FOR FUTURE DIRECTION
Mary Ann Sondrini, EdM, Eagleson Institute
James M. Welch, Elizabeth R. Griffin Research Foundation

4:45 CONCLUSION

“COLLOQUIUM” IS FROM THE LATIN COLLOQU, MEANING TO TALK TOGETHER.

eagleson.org/OCC
Beyond the ABCs of IBCs
Institutional Biosafety Committee Conference

Preventing and Treating Biological Exposures
Occupational Health Colloquium

Two Conferences, One Location, One Week

JUNE 7-9, 2015
eagleson.org/IBC

JUNE 9-11, 2015
eagleson.org/OCC